The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology.

Int J Methods Psychiatr Res 2010 Dec;19(4):195-210

UPC KUL Campus Kortenberg, Kortenberg, Belgium.

Patients with schizophrenia present a two- to three-fold higher prevalence of diabetes, of metabolic syndrome and of cardiovascular morbidity. The reason for this increased prevalence may involve intrinsic vulnerability, lifestyle factors and iatrogenic effects of antipsychotic drugs. The objective of this multinational, cross-sectional, pharmacoepidemiological study was to determine the prevalence of diabetes, lipid disorders, obesity, hypertension and the metabolic syndrome in patients with schizophrenia treated with antipsychotic drugs. Particular attention was taken to acquire data on a wide a range as possible of demographic, clinical and lifestyle variables that may influence the risk of metabolic disorders, which were taken into account in the calculation of prevalence data by propensity scoring. The study included 2270 subjects from 16 European countries, predominantly from Central and Eastern Europe. The proportion of subjects presenting the pathologies of interest was relatively high, ranging from 28% for glycaemic disorders to 70% for lipid disorders.

Download full-text PDF

Source
http://dx.doi.org/10.1002/mpr.322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878539PMC
December 2010
18 Reads

Publication Analysis

Top Keywords

patients schizophrenia
12
antipsychotic drugs
12
lipid disorders
8
schizophrenia treated
8
treated antipsychotic
8
metabolic disorders
8
metabolic syndrome
8
prevalence diabetes
8
diabetes metabolic
8
disorders
5
range demographic
4
demographic clinical
4
acquire data
4
wide range
4
clinical lifestyle
4
data wide
4
variables influence
4
disorders account
4
risk metabolic
4
influence risk
4

Similar Publications